Today is a light funding day, but the deals that did surface are concentrated in a few high-conviction areas. Over the past 16 hours, the most notable rounds totaled roughly $40 million to $45 million, with investors backing AI infrastructure, precision oncology, and neuropsychiatric biotech. Three of the deals (Kasvu Therapeutics, Clastix, Prevision Medicine) alone account for essentially all the capital, with Kasvu’s €30 million Series A (?$34M) dominating the count. Two of the three are explicitly AI?related (Clastix’s cloud?infra platform and Prevision’s precision oncology platform), and the third is cutting?edge biotech (Kasvu’s neuroplasticity drug). Geography is narrowly European (Finland,…